Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients
author:
Maina Theodosia, Konijnenbergb Mark W., KolencPeitl Petra, Garnuszek Piotr, Nock Berthold A., Kaloudi Aikaterini, Kroselj Marko, Zaletel Katja, Maecke Helmut, Mansi Rosalba, Erba Paola, von Guggenberg Elisabeth, Hubalewska-Dydejczyk Alicja , Mikołajczak Renata, Decristoforo Clemens